Phase 2Completed
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma
- Sponsor
- Corixa Corporation (Industry)
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Iodine-131 Anti-B1 Antibody; Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
- Ages
- adults, older adults
- Registry
- NCT00022945
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.
History
Last registry update
Registered